Ascelia Q2: Further interest and scientific support ahead of launch - Redeye

Ascelia’s pivotal study seems to be on track, and the company repeats the goal to reach the full enrolment of 50 patients in 2022. Ascelia can also point to considerable professional interest and confirmed scientific support ahead of the pivotal readout and the subsequent launch. Later, during Q3 2022 we can expect results from the supporting Hepatic Impairment Study.

Länk till analysen i sin helhet: https://www.redeye.se/research/852133/ascelia-q2-further-interest-and-scientific-support-ahead-of-launch?utm_source=finwire&utm_medium=RSS